Joel Neal, Nick Pavlakis, Sang-We Kim, Yasushi Goto, Sun Min Lim, Giannis Mountzios, Elena Fountzilas, Anastasia Mochalova, Daniel C Christoph, Alessandra Bearz, Xavier Quantin, Ramon Palmero, Vladan Antic, Elaine Chun, Tirupathi Rao Edubilli, Ya-Chen Lin, Mahrukh Huseni, Marcus Ballinger, Vilma Graupner, Dominic Curran, Piet Vervaet, Thomas Newsom-Davis
PURPOSE: Although checkpoint inhibitors have improved first-line treatment for non-small cell lung cancer (NSCLC), a therapeutic need remains for patients whose disease does not respond or who experience disease progression after anti-PD-L1/PD-1 immunotherapy. CONTACT-01 (ClinicalTrials.gov identifier: NCT04471428) evaluated atezolizumab plus cabozantinib versus docetaxel in patients with metastatic NSCLC who developed disease progression after concurrent or sequential treatment with anti-PD-L1/PD-1 and platinum-containing chemotherapy...
March 29, 2024: Journal of Clinical Oncology